Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer


The purpose of this study is to determine whether UTD1 Injection in combination with capecitabine is effective in the treatment of advanced metastatic breast cancer using capecitabine as a control.

Full Title of Study: “Phase III Clinical Trials of UTD1 Injection Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced and Metastatic Breast Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2016


  • Drug: UTD1 Injection plus capecitabine
  • Drug: Capecitabine

Arms, Groups and Cohorts

  • Experimental: UTD1 Injection plus capecitabine
    • UTD1 Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle; Capecitabine: 2000 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
  • Active Comparator: capecitabine
    • Capecitabine: 2500 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Clinical Trial Outcome Measures

Primary Measures

  • Progresssion free survival (PFS)
    • Time Frame: 2.0 years

Secondary Measures

  • Overall survival (OS)
    • Time Frame: 4 years
  • Objective Response Rate(ORR)
    • Time Frame: 1.5 years

Participating in This Clinical Trial

Inclusion Criteria

1. Histologically and/or cytologically diagnosed patients with advanced, metastatic breast cancer,or lacking standard therapy or being failed to or recurrent after standard therapy;

2. Patients who have previously treated with ≤4 chemotherapeutic regimes;

3. Patients who have previously treated with an anthracyclin antibiotics and a taxane;

4. Age 18 -70 years old, ECOG performance status of 0-2; Life expectancy of 3 months or more;

5. Patients with at least 1 measurable target lesion determined by CT within 2 weeks prior to enrollment;

6. Neuropathy <CTC2 degree (NCI CTC4.03)within 4 weeks prior to enrollment;

7. Basically normal results from routine blood test within 1 week prior to enrollment;

8. Basically normal liver and renal functions within 1 week prior to enrollment;

9. No abnormal function for major internal organs, no heart diseases.

Exclusion Criteria

1. Received chemotherapy, radiotherapy, therapies with hormones or molecularly targeted drugs 4 weeks prior to enrollment, or received other chemotherapies while participating in this trial;

2. Patients with documented hypersensitivity to Cremophor EL, or patients with previous taxane treatment related SAE;

3. Patients of pregnancy or breast feeding;

4. Patients with previous standard capecitabine treatment ineffective, or patients received standard capecitabine treatment effective, but with less than 6 months of capecitabine clearance period;

5. Patients with uncontrolled brain metastasis or bone metastasis, which plan for recent surgery or local radiotherapy, or other emergency treatment;

6. Patients combined with severe and /or uncontrolled medical conditions, including severe cardiovascular disease, uncontrolled diabetes and high blood pressure, severe infection, severe gastrointestinal ulceration, and patients with incontrollable psychiatric history;

7. Patients with poor compliance;

8. Patients not fitted for this study determined by the investigators.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Beijing Biostar Technologies, Ltd
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • B Xu, doctor, Principal Investigator, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.